Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMA 950

Next Previous
Search
Drug Profile

IMA 950

Alternative Names: IMA-950

Latest Information Update: 24 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator immatics biotechnologies GmbH
  • Developer Cancer Research UK; Immatics N.V.; National Cancer Institute (USA); Oncovir; University Hospitals of Geneva
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioblastoma; Glioma

Most Recent Events

  • 23 Sep 2020 Discontinued - Phase-I for Glioblastoma (Combination therapy, Newly diagnosed) in United Kingdom (Intradermal) (Immatics N.V. pipeline, September 2020)
  • 23 Sep 2020 Discontinued - Phase-I for Glioblastoma (Combination therapy, Second-line therapy or greater) in USA (Intradermal) (Immatics N.V. pipeline, September 2020)
  • 23 Sep 2020 Discontinued - Phase-I for Glioma (Combination therapy, Second-line therapy or greater, Neoadjuvant therapy) in USA (SC) (Immatics N.V. pipeline, September 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top